CERo Therapeutics - CERO Income before deduction of interest, taxes and amortization

Graphic logo of CERo Therapeutics Holdings (CERO)

CERo Therapeutics (CERO) is developing an immune reprogramming system via the CER-T platform to combat tumors. The company is recruiting world-leading engineers to ensure the stability of its scientific core. However, high R&D costs and the risk of side effects create a threat of capital deficiency. The metric reflects current dynamics, while the total EBITDA on the chart demonstrates the asset's real financial power.

CERO CERo Therapeutics Holdings Operating profit EBITDA (07/04/2022 - 11/12/2026)

Summary analytical data breakdowns for CERo Therapeutics Holdings (CERO)

- market value and analyst target forecast:
Market Price CERo Therapeutics Holdings, Inc.|CERO - Consensus Target
- issuer market value details:
Market Value CERo Therapeutics|CERO - Enterprise Value
- book capitalization information:
Accounting Value per Share CERo Therapeutics|CERO - Book Capitalization|Market-to-Book Ratio cero.bio|CERO - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity CERo Therapeutics|CERO - Long-Term Debt to Equity|Short-Term Debt to Equity CERo Therapeutics Holdings, Inc.|CERO - Company Total Debt|Debt to Net Assets Ratio CERo Therapeutics|CERO - Company Long-Term Debts|Short-Term Indebtedness CERo Therapeutics|Immediate Liquidity cero.bio
- earnings and multiples data:
CERO - Company Net Income|Net Profit Forecast CERo Therapeutics|CERO - P/E Multiple|Projected Price to Earnings Ratio CERo Therapeutics Holdings, Inc.|CERO - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation CERo Therapeutics|CERO - Operating profit before deduction of amortization|Earnings per share for the last four quarters CERo Therapeutics|CERO - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months cero.bio|CERO - Earnings growth in current year|Expected net earnings per share growth next year CERo Therapeutics
Fundamental company valuation:CERo Therapeutics
Manufactured products of CERo Therapeutics Holdings, Inc.

The biopharmaceutical potential of CERo Therapeutics (CERO) in developing non-toxic T-cell technologies requires precise cash flow monitoring to evaluate the effectiveness of R&D investments. By analyzing EBITDA, an investor can discern real operating profit, making it possible to identify dangerous liquidity anomalies that often serve as precursors to deep market corrections and capital drawdowns.

Who CERo Therapeutics competes with

Legend Biotech Corp. (LEGN) - Profit before interest, taxes and amortization|SANA: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AUTL (autolus.com)|ALLO: Operating profit EBITDA|Operating profit before deduction of amortization Selecta Biosciences|CLLS (Cellectis SA) - Operating profit EBITDA|Profit before interest, taxes and amortization Caribou Biosciences, Inc CRBU|Profit before payment of interest, taxes and amortization Instil Bio, Inc. (TIL)|Profit before payment of interest, taxes and amortization GNTA (genenta.com)|Profit before payment of interest, taxes and amortization Century Therapeutics, Inc. IPSC|Jasper Therapeutics Inc - Profit before payment of interest, taxes and amortization|SNTI: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization ADAP (Adaptimmune)|TCRT: Operating profit EBITDA|Operating profit before depreciation charges Achilles Therapeutics plc ACHL|CRGX (CARGO Therapeutics, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Poseida Therapeutics Inc PSTX|Profit before payment of interest, taxes and amortization 2seventy Bio (TSVT)|Gracell - Operating profit before amortization